With more than 50 partners involved, the EYE partnership supports 40 at-risk countries in Africa and the Americas to prevent, detect, and respond to yellow fever suspected cases and outbreaks.

The Eliminate Yellow fever Epidemics (EYE) Strategy launched in 2017 is an unprecedented initiative.

There is currently no specific anti-viral drug for yellow fever.

Good supportive treatment in hospitals improves survival rates.

The vaccine provides effective immunity within 10 days for 80-100% of people vaccinated, and within 30 days for more than 99% of people vaccinated. A booster dose of the vaccine is not needed. A single dose of yellow fever vaccine is sufficient to grant sustained immunity and life-long protection against yellow fever disease.

Yellow fever is prevented by an extremely effective vaccine, which is safe and affordable.

In these conditions, infected mosquitoes of the Aedes aegypti species transmit the virus from person to person.

Large epidemics of yellow fever occur when infected people introduce the virus into heavily populated areas with high mosquito density and where most people have little or no immunity, due to lack of vaccination.

The virus is endemic in tropical areas of Africa and Central and South America.

A small proportion of patients who contract the virus develop severe symptoms and approximately half of those die within 7 to 10 days.

Symptoms of yellow fever include fever, headache, jaundice, muscle pain, nausea, vomiting and fatigue.

The 'yellow' in the name refers to the jaundice that affects some patients.

Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitoes.

That affects me